Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2911080 | 0.89 | SIGMAR1 (0.56) | SIGMAR1ATMTAAR1RAB9ANPC1 | |
| SCHEMBL28475113 | 0.87 | SIGMAR1 (0.59) | SIGMAR1ATMTAAR1RAB9ANPC1 | |
| Hydrochloric Acid SCHEMBL10616388 | 0.84 | SIGMAR1 (0.56) | SIGMAR1ATMTAAR1RAB9ANPC1 | |
| SCHEMBL1258404 | 0.84 | ATM (0.54) | SIGMAR1ATMTAAR1RAB9ANPC1 | |
| Iodide SCHEMBL21800796 | 0.82 | ATM (0.52) | SIGMAR1ATMTAAR1RAB9ANPC1 | |
| Hydrochloric Acid SCHEMBL27717825 | 0.82 | ATM (0.52) | SIGMAR1ATMTAAR1RAB9ANPC1 | |
| SCHEMBL5506614 | 0.80 | KDM4E (0.45) | SIGMAR1MAPTLMNACYP3A4IDO1 | |
| SCHEMBL5532769 | 0.79 | SIGMAR1 (0.53) | SIGMAR1HPGDMEN1KMT2AL3MBTL1 | |
| SCHEMBL1829762 | 0.78 | NPC1 (0.50) | SIGMAR1ATMTAAR1RAB9ANPC1 | |
| SCHEMBL27481442 | 0.76 | SIGMAR1 (0.54) | SIGMAR1HPGDMEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720030-A1 | ASYMMETRIC PHENYLALKYLAMINES | Alexander Shulgin Research Institute, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4673430-A2 | PHENYLALKYLAMINE PRODRUGS | Alexander Shulgin Research Institute, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4673127-A1 | DEUTERATED AND FLUORINATED EMPATHOGENS | Alexander Shulgin Research Institute, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20250388529-A1 | N-Substituted Phenylalkylamines and Their Use as Therapeutic Agents | ALEXANDER SHULGIN RES INSTITUTE INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12465578-B2 | Substituted alpha-ethyl phenylalkylamines | ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| EP-4618981-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | Remedi, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20250248969-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | REMEDI INC (US) | 2025-08-07 | — | — | US | disclosed |
| US-20250195471-A1 | ASYMMETRIC ALLYL TRYPTAMINES | ALEXANDER SHULGIN RES INSTITUTE INC (US) | 2025-06-19 | — | — | US | disclosed |
| CN-119923380-A | N-substituted phenylalkylamines and their use as therapeutic agents | 亚历山大舒尔金研究所有限公司 | 2025-05-02 | — | — | CN | disclosed |
| EP-4543833-A1 | N-SUBSTITUTED PHENYLALKYLAMINES AND THEIR USE AS THERAPEUTIC AGENTS | Alexander Shulgin Research Institute, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| CN-118234491-A | Hallucinogen-fatty acid combinations | 明德赛特制药公司 | 2024-06-21 | — | — | CN | disclosed |
| WO-2024108195-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | REMEDI, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024091523-A1 | CONFORMATIONALLY RESTRICTED PHENETHYLAMINE ANALOGS | 2A BIOSCIENCES, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024006226-A1 | N-SUBSTITUTED PHENYLALKYLAMINES AND THEIR USE AS THERAPEUTIC AGENTS | ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2023049480-A1 | SUBSTITUTED PHENYLALKYLAMINES | ALEXANDER SHULGIN RESEARCH INSTITUTE (US) | 2023-03-30 | — | — | WO | disclosed |
| WO-2023034645-A2 | ASYMMETRIC ALLYL TRYPTAMINES | ALEXANDER SHULGIN RESEARCH INSTITUTE (US) | 2023-03-09 | — | — | WO | disclosed |
| WO-2023283386-A2 | SAFER PSYCHOACTIVE COMPOSITIONS | ARCADIA MEDICINE, INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| EP-0671928-A4 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS. | CHIRON CORP (US) | 1997-04-23 | — | — | EP | disclosed |
| EP-0671928-A1 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS | CHIRON CORPORATION (US) | 1995-09-20 | — | — | EP | disclosed |
| WO-1994006451-A1 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS | CHIRON CORPORATION (US) | 1994-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388529-A1 | N-Substituted Phenylalkylamines and Their Use as Therapeutic Agents | CNR2, CNR1, HCN3 | SIGMAR1 62/4885ATM 3680/4885TAAR1 24/4885 |
| US-20250195471-A1 | ASYMMETRIC ALLYL TRYPTAMINES | TPH2, TPH1, HTR2A | SIGMAR1 200/4885ATM 2738/4885TAAR1 37/4885 |
| US-12465578-B2 | Substituted alpha-ethyl phenylalkylamines | PNMT, SLC18A2, SLC1A2 | SIGMAR1 66/4885ATM 2846/4885TAAR1 48/4885 |
| US-20250248969-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | MAOA, MAOB, HTR1A | SIGMAR1 92/4885ATM 2590/4885TAAR1 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.